Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells

WeiWei Li, Dan Su, Hiroo Mizobuchi, Daniel S. Martin, Bin Gu, Richard Gorlick, Peter Cole, Joseph R. Bertino

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of this enzyme was correlated with increased sensitivity to L-alanosine and/or 6-methylmercaptopurine. We used a polyclonal antibody to measure the expression of MTAP in soft tissue sarcoma cell lines and in fresh tumor samples. Transfection of the HT-1080 cell line with a plasmid containing the cDNA for the MTAP gene was also performed to generate cell lines for in vitro and in vivo comparative sensitivity studies. MTAP was not expressed in 8 of 21 fresh STS tumors. The expression of MTAP was also not detectable in 3 of the 11 soft tissue sarcoma cell lines (HT-1080, HS42, and M-9110). These three cell lines were more sensitive to L-alanosine, a potent inhibitor of de novo AMP synthesis, and to an inhibitor of de novo purine nucleotide synthesis, 6-methylmercaptopurine riboside (MMPR). The IC50 values for L-alanosine and MMPR were >20-fold lower in MTAP-deficient cells than in MTAP-positive cells. Restoration of MTAP into HT-1080 MTAP-deficient cells also led to decreased sensitivity to L-alanosine and MMPR. An in vivo study using HT-1080 cell tumors with and without MTAP expression confirmed that tumors lacking MTAP were more sensitive to L-alanosine than tumors expressing MTAP. These results provide the basis for selective therapy using inhibitors of de novo purine nucleotide synthesis such as L-alanosine or MMPR to treat patients with STS lacking this enzyme.

Original languageEnglish (US)
Pages (from-to)373-379
Number of pages7
JournalOncology Research
Volume14
Issue number7-8
StatePublished - 2004
Externally publishedYes

Fingerprint

alanosine
Sarcoma
Methylthioinosine
Cell Line
Purine Nucleotides
Neoplasms
6-methylthiopurine
5'-methylthioadenosine phosphorylase

Keywords

  • Drug sensitivity
  • L-Alanosine
  • Methylmercaptopurine riboside (MMPR)
  • Methylthioadenosine phosphorylase (MTAP)
  • Soft tissue sarcoma cells

ASJC Scopus subject areas

  • Cancer Research

Cite this

Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. / Li, WeiWei; Su, Dan; Mizobuchi, Hiroo; Martin, Daniel S.; Gu, Bin; Gorlick, Richard; Cole, Peter; Bertino, Joseph R.

In: Oncology Research, Vol. 14, No. 7-8, 2004, p. 373-379.

Research output: Contribution to journalArticle

Li, W, Su, D, Mizobuchi, H, Martin, DS, Gu, B, Gorlick, R, Cole, P & Bertino, JR 2004, 'Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells', Oncology Research, vol. 14, no. 7-8, pp. 373-379.
Li, WeiWei ; Su, Dan ; Mizobuchi, Hiroo ; Martin, Daniel S. ; Gu, Bin ; Gorlick, Richard ; Cole, Peter ; Bertino, Joseph R. / Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. In: Oncology Research. 2004 ; Vol. 14, No. 7-8. pp. 373-379.
@article{4b3dba46c4554d51b53a9b60e0e00e61,
title = "Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells",
abstract = "The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of this enzyme was correlated with increased sensitivity to L-alanosine and/or 6-methylmercaptopurine. We used a polyclonal antibody to measure the expression of MTAP in soft tissue sarcoma cell lines and in fresh tumor samples. Transfection of the HT-1080 cell line with a plasmid containing the cDNA for the MTAP gene was also performed to generate cell lines for in vitro and in vivo comparative sensitivity studies. MTAP was not expressed in 8 of 21 fresh STS tumors. The expression of MTAP was also not detectable in 3 of the 11 soft tissue sarcoma cell lines (HT-1080, HS42, and M-9110). These three cell lines were more sensitive to L-alanosine, a potent inhibitor of de novo AMP synthesis, and to an inhibitor of de novo purine nucleotide synthesis, 6-methylmercaptopurine riboside (MMPR). The IC50 values for L-alanosine and MMPR were >20-fold lower in MTAP-deficient cells than in MTAP-positive cells. Restoration of MTAP into HT-1080 MTAP-deficient cells also led to decreased sensitivity to L-alanosine and MMPR. An in vivo study using HT-1080 cell tumors with and without MTAP expression confirmed that tumors lacking MTAP were more sensitive to L-alanosine than tumors expressing MTAP. These results provide the basis for selective therapy using inhibitors of de novo purine nucleotide synthesis such as L-alanosine or MMPR to treat patients with STS lacking this enzyme.",
keywords = "Drug sensitivity, L-Alanosine, Methylmercaptopurine riboside (MMPR), Methylthioadenosine phosphorylase (MTAP), Soft tissue sarcoma cells",
author = "WeiWei Li and Dan Su and Hiroo Mizobuchi and Martin, {Daniel S.} and Bin Gu and Richard Gorlick and Peter Cole and Bertino, {Joseph R.}",
year = "2004",
language = "English (US)",
volume = "14",
pages = "373--379",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "7-8",

}

TY - JOUR

T1 - Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells

AU - Li, WeiWei

AU - Su, Dan

AU - Mizobuchi, Hiroo

AU - Martin, Daniel S.

AU - Gu, Bin

AU - Gorlick, Richard

AU - Cole, Peter

AU - Bertino, Joseph R.

PY - 2004

Y1 - 2004

N2 - The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of this enzyme was correlated with increased sensitivity to L-alanosine and/or 6-methylmercaptopurine. We used a polyclonal antibody to measure the expression of MTAP in soft tissue sarcoma cell lines and in fresh tumor samples. Transfection of the HT-1080 cell line with a plasmid containing the cDNA for the MTAP gene was also performed to generate cell lines for in vitro and in vivo comparative sensitivity studies. MTAP was not expressed in 8 of 21 fresh STS tumors. The expression of MTAP was also not detectable in 3 of the 11 soft tissue sarcoma cell lines (HT-1080, HS42, and M-9110). These three cell lines were more sensitive to L-alanosine, a potent inhibitor of de novo AMP synthesis, and to an inhibitor of de novo purine nucleotide synthesis, 6-methylmercaptopurine riboside (MMPR). The IC50 values for L-alanosine and MMPR were >20-fold lower in MTAP-deficient cells than in MTAP-positive cells. Restoration of MTAP into HT-1080 MTAP-deficient cells also led to decreased sensitivity to L-alanosine and MMPR. An in vivo study using HT-1080 cell tumors with and without MTAP expression confirmed that tumors lacking MTAP were more sensitive to L-alanosine than tumors expressing MTAP. These results provide the basis for selective therapy using inhibitors of de novo purine nucleotide synthesis such as L-alanosine or MMPR to treat patients with STS lacking this enzyme.

AB - The aim of this study was to examine the expression of methylthioadenosine phosphorylase (MTAP) in 21 fresh tumor samples from patients with soft tissue sarcomas (STS) and 11 human soft tissue sarcoma cell lines, and to determine if loss of expression of this enzyme was correlated with increased sensitivity to L-alanosine and/or 6-methylmercaptopurine. We used a polyclonal antibody to measure the expression of MTAP in soft tissue sarcoma cell lines and in fresh tumor samples. Transfection of the HT-1080 cell line with a plasmid containing the cDNA for the MTAP gene was also performed to generate cell lines for in vitro and in vivo comparative sensitivity studies. MTAP was not expressed in 8 of 21 fresh STS tumors. The expression of MTAP was also not detectable in 3 of the 11 soft tissue sarcoma cell lines (HT-1080, HS42, and M-9110). These three cell lines were more sensitive to L-alanosine, a potent inhibitor of de novo AMP synthesis, and to an inhibitor of de novo purine nucleotide synthesis, 6-methylmercaptopurine riboside (MMPR). The IC50 values for L-alanosine and MMPR were >20-fold lower in MTAP-deficient cells than in MTAP-positive cells. Restoration of MTAP into HT-1080 MTAP-deficient cells also led to decreased sensitivity to L-alanosine and MMPR. An in vivo study using HT-1080 cell tumors with and without MTAP expression confirmed that tumors lacking MTAP were more sensitive to L-alanosine than tumors expressing MTAP. These results provide the basis for selective therapy using inhibitors of de novo purine nucleotide synthesis such as L-alanosine or MMPR to treat patients with STS lacking this enzyme.

KW - Drug sensitivity

KW - L-Alanosine

KW - Methylmercaptopurine riboside (MMPR)

KW - Methylthioadenosine phosphorylase (MTAP)

KW - Soft tissue sarcoma cells

UR - http://www.scopus.com/inward/record.url?scp=4043099036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043099036&partnerID=8YFLogxK

M3 - Article

C2 - 15301428

AN - SCOPUS:4043099036

VL - 14

SP - 373

EP - 379

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 7-8

ER -